• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

联合建模纵向和生存数据的样本量和功效确定。

Sample size and power determination in joint modeling of longitudinal and survival data.

机构信息

Department of Biostatistics, University of North Carolina, Chapel Hill, NC 27599, U.S.A.

出版信息

Stat Med. 2011 Aug 15;30(18):2295-309. doi: 10.1002/sim.4263. Epub 2011 May 17.

DOI:10.1002/sim.4263
PMID:21590793
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3278672/
Abstract

Owing to the rapid development of biomarkers in clinical trials, joint modeling of longitudinal and survival data has gained its popularity in the recent years because it reduces bias and provides improvements of efficiency in the assessment of treatment effects and other prognostic factors. Although much effort has been put into inferential methods in joint modeling, such as estimation and hypothesis testing, design aspects have not been formally considered. Statistical design, such as sample size and power calculations, is a crucial first step in clinical trials. In this paper, we derive a closed-form sample size formula for estimating the effect of the longitudinal process in joint modeling, and extend Schoenfeld's sample size formula to the joint modeling setting for estimating the overall treatment effect. The sample size formula we develop is quite general, allowing for p-degree polynomial trajectories. The robustness of our model is demonstrated in simulation studies with linear and quadratic trajectories. We discuss the impact of the within-subject variability on power and data collection strategies, such as spacing and frequency of repeated measurements, in order to maximize the power. When the within-subject variability is large, different data collection strategies can influence the power of the study in a significant way. Optimal frequency of repeated measurements also depends on the nature of the trajectory with higher polynomial trajectories and larger measurement error requiring more frequent measurements.

摘要

由于临床试验中生物标志物的快速发展,近年来纵向和生存数据的联合建模因其能够减少偏差并提高治疗效果和其他预后因素评估的效率而受到关注。尽管在联合建模的推断方法(如估计和假设检验)方面已经做了很多工作,但设计方面尚未得到正式考虑。统计设计,如样本量和功效计算,是临床试验的关键第一步。在本文中,我们推导出了一种用于估计联合建模中纵向过程效果的闭式样本量公式,并将 Schoenfeld 的样本量公式扩展到联合建模环境中,以估计总体治疗效果。我们开发的样本量公式非常通用,允许 p 度多项式轨迹。线性和二次轨迹的模拟研究证明了我们模型的稳健性。我们讨论了个体内变异性对功效的影响以及数据收集策略,如重复测量的间隔和频率,以最大程度地提高功效。当个体内变异性较大时,不同的数据收集策略会对研究的功效产生重大影响。最佳重复测量频率还取决于轨迹的性质,具有较高多项式轨迹和较大测量误差的轨迹需要更频繁的测量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef3/3278672/1b4c1c384dc1/nihms351426f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef3/3278672/1b4c1c384dc1/nihms351426f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ef3/3278672/1b4c1c384dc1/nihms351426f1.jpg

相似文献

1
Sample size and power determination in joint modeling of longitudinal and survival data.联合建模纵向和生存数据的样本量和功效确定。
Stat Med. 2011 Aug 15;30(18):2295-309. doi: 10.1002/sim.4263. Epub 2011 May 17.
2
Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.评估纵向数据与生存数据联合模型中的模型拟合及其在癌症临床试验中的应用。
Stat Med. 2014 Nov 30;33(27):4715-33. doi: 10.1002/sim.6269. Epub 2014 Jul 20.
3
Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints.具有事件发生时间终点的分层临床试验中的异质性治疗效果。
Biom J. 2017 May;59(3):511-530. doi: 10.1002/bimj.201600047. Epub 2017 Mar 6.
4
Sample size determination for the association between longitudinal and time-to-event outcomes using the joint modeling time-dependent slopes parameterization.使用联合建模时变斜率参数化方法确定纵向和生存结局之间关联的样本量。
Stat Med. 2022 Dec 30;41(30):5810-5829. doi: 10.1002/sim.9595. Epub 2022 Oct 28.
5
Sample size determination for longitudinal designs with binary response.具有二分类响应的纵向设计的样本量确定。
Stat Med. 2014 Sep 28;33(22):3781-800. doi: 10.1002/sim.6203. Epub 2014 May 12.
6
Revisiting methods for modeling longitudinal and survival data: Framingham Heart Study.重新审视建模纵向和生存数据的方法:弗雷明汉心脏研究。
BMC Med Res Methodol. 2021 Feb 10;21(1):29. doi: 10.1186/s12874-021-01207-y.
7
Comparing statistical methods in assessing the prognostic effect of biomarker variability on time-to-event clinical outcomes.比较评估生物标志物变异性对时间事件临床结局预后效果的统计学方法。
BMC Med Res Methodol. 2022 Jul 22;22(1):201. doi: 10.1186/s12874-022-01686-7.
8
Sample size considerations for the evaluation of prognostic factors in survival analysis.生存分析中评估预后因素时的样本量考量
Stat Med. 2000 Feb 29;19(4):441-52. doi: 10.1002/(sici)1097-0258(20000229)19:4<441::aid-sim349>3.0.co;2-n.
9
Sample size estimation for GEE method for comparing slopes in repeated measurements data.用于比较重复测量数据中斜率的广义估计方程(GEE)方法的样本量估计
Stat Med. 2003 Apr 30;22(8):1305-15. doi: 10.1002/sim.1384.
10
Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.涉及重复二分观测的群体药效学实验的样本量计算
J Biopharm Stat. 2008;18(6):1212-27. doi: 10.1080/10543400802375845.

引用本文的文献

1
Bayesian joint longitudinal and survival modeling of bipolar symptom burden and time to symptomatic recovery of patients with bipolar disorder at Jimma University Medical Center, Jimma, Ethiopia.埃塞俄比亚吉马市吉马大学医学中心双相情感障碍患者双相症状负担及症状恢复时间的贝叶斯联合纵向和生存模型。
BMC Psychiatry. 2025 Apr 5;25(1):337. doi: 10.1186/s12888-025-06776-6.
2
Viral load change and time to death among adult HIV/AIDS patients on ART after test-and-treat in Northwest Ethiopia: a retrospective multi-center follow-up study using Bayesian joint modeling.埃塞俄比亚西北部接受检测即治疗的成年艾滋病病毒/艾滋病患者接受抗逆转录病毒治疗后的病毒载量变化及死亡时间:一项使用贝叶斯联合模型的回顾性多中心随访研究
Front Public Health. 2025 Mar 18;13:1418999. doi: 10.3389/fpubh.2025.1418999. eCollection 2025.
3
Bayesian joint models for multi-regional clinical trials.贝叶斯联合模型在多区域临床试验中的应用。
Biostatistics. 2024 Jul 1;25(3):852-866. doi: 10.1093/biostatistics/kxad023.
4
Sample size determination for the association between longitudinal and time-to-event outcomes using the joint modeling time-dependent slopes parameterization.使用联合建模时变斜率参数化方法确定纵向和生存结局之间关联的样本量。
Stat Med. 2022 Dec 30;41(30):5810-5829. doi: 10.1002/sim.9595. Epub 2022 Oct 28.
5
Survival time to complications of congestive heart failure patients at Felege Hiwot comprehensive specialized referral hospital, Bahir Dar, Ethiopia.埃塞俄比亚巴赫达尔费莱格·希沃特综合专科医院充血性心力衰竭并发症患者的生存时间。
PLoS One. 2022 Oct 20;17(10):e0276440. doi: 10.1371/journal.pone.0276440. eCollection 2022.
6
Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies.肿瘤学临床试验中事件时间终点分析的统计学考虑:以 CAR-T 免疫疗法研究为例。
Clin Cancer Res. 2022 Sep 15;28(18):3940-3949. doi: 10.1158/1078-0432.CCR-22-0560.
7
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy in Heart Transplantation: New Strategies and Preliminary Results in Endomyocardial Biopsies.他克莫司治疗药物监测——心脏移植中的个体化治疗:心内膜心肌活检的新策略及初步结果
Pharmaceutics. 2022 Jun 12;14(6):1247. doi: 10.3390/pharmaceutics14061247.
8
Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials.联合建模可用于回答随机临床试验中的各种研究问题。
J Clin Epidemiol. 2022 Jul;147:32-39. doi: 10.1016/j.jclinepi.2022.03.009. Epub 2022 Mar 26.
9
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.ctDNA 动态复发风险和辅助化疗获益预测在可切除 NSCLC 中的应用。
Nat Commun. 2021 Nov 19;12(1):6770. doi: 10.1038/s41467-021-27022-z.
10
Bayesian design of clinical trials using joint models for longitudinal and time-to-event data.使用纵向和生存数据联合模型进行临床试验的贝叶斯设计。
Biostatistics. 2022 Apr 13;23(2):591-608. doi: 10.1093/biostatistics/kxaa044.

本文引用的文献

1
Basic concepts and methods for joint models of longitudinal and survival data.纵向和生存数据联合模型的基本概念和方法。
J Clin Oncol. 2010 Jun 1;28(16):2796-801. doi: 10.1200/JCO.2009.25.0654. Epub 2010 May 3.
2
Joint modeling of survival and longitudinal data: likelihood approach revisited.生存数据与纵向数据的联合建模:似然方法再探讨
Biometrics. 2006 Dec;62(4):1037-43. doi: 10.1111/j.1541-0420.2006.00570.x.
3
Joint models for multivariate longitudinal and multivariate survival data.多变量纵向数据和多变量生存数据的联合模型。
Biometrics. 2006 Jun;62(2):432-45. doi: 10.1111/j.1541-0420.2005.00448.x.
4
Using trajectories from a bivariate growth curve as predictors in a Cox regression model.在Cox回归模型中使用双变量生长曲线的轨迹作为预测因子。
Stat Med. 2007 Feb 20;26(4):800-11. doi: 10.1002/sim.2558.
5
Simultaneous modelling of survival and longitudinal data with an application to repeated quality of life measures.生存数据与纵向数据的联合建模及其在重复生活质量测量中的应用
Lifetime Data Anal. 2005 Jun;11(2):151-74. doi: 10.1007/s10985-004-0381-0.
6
An estimator for the proportional hazards model with multiple longitudinal covariates measured with error.一种用于具有测量误差的多个纵向协变量的比例风险模型的估计量。
Biostatistics. 2002 Dec;3(4):511-28. doi: 10.1093/biostatistics/3.4.511.
7
Joint modelling of longitudinal measurements and event time data.纵向测量数据与事件时间数据的联合建模
Biostatistics. 2000 Dec;1(4):465-80. doi: 10.1093/biostatistics/1.4.465.
8
A Bayesian semiparametric joint hierarchical model for longitudinal and survival data.一种用于纵向数据和生存数据的贝叶斯半参数联合分层模型。
Biometrics. 2003 Jun;59(2):221-8. doi: 10.1111/1541-0420.00028.
9
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).多柔比星、紫杉醇以及多柔比星与紫杉醇联合作为转移性乳腺癌一线化疗的Ⅲ期试验:一项组间试验(E1193)
J Clin Oncol. 2003 Feb 15;21(4):588-92. doi: 10.1200/JCO.2003.08.013.
10
Surrogate markers and joint models for longitudinal and survival data.纵向数据和生存数据的替代指标与联合模型
Control Clin Trials. 2002 Dec;23(6):626-34. doi: 10.1016/s0197-2456(02)00234-9.